Cargando…
Extra energy for hearts with a genetic defect: ENERGY trial
AIMS: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decre...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439046/ https://www.ncbi.nlm.nih.gov/pubmed/30767167 http://dx.doi.org/10.1007/s12471-019-1239-0 |
_version_ | 1783407192671518720 |
---|---|
author | van Driel, B. O. van Rossum, A. C. Michels, M. Huurman, R. van der Velden, J. |
author_facet | van Driel, B. O. van Rossum, A. C. Michels, M. Huurman, R. van der Velden, J. |
author_sort | van Driel, B. O. |
collection | PubMed |
description | AIMS: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. METHODS: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [(11)C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. CONCLUSION: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy. |
format | Online Article Text |
id | pubmed-6439046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bohn Stafleu van Loghum |
record_format | MEDLINE/PubMed |
spelling | pubmed-64390462019-04-15 Extra energy for hearts with a genetic defect: ENERGY trial van Driel, B. O. van Rossum, A. C. Michels, M. Huurman, R. van der Velden, J. Neth Heart J Original Article – Design Study Article AIMS: Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. METHODS: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [(11)C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. CONCLUSION: The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy. Bohn Stafleu van Loghum 2019-02-14 2019-04 /pmc/articles/PMC6439046/ /pubmed/30767167 http://dx.doi.org/10.1007/s12471-019-1239-0 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article – Design Study Article van Driel, B. O. van Rossum, A. C. Michels, M. Huurman, R. van der Velden, J. Extra energy for hearts with a genetic defect: ENERGY trial |
title | Extra energy for hearts with a genetic defect: ENERGY trial |
title_full | Extra energy for hearts with a genetic defect: ENERGY trial |
title_fullStr | Extra energy for hearts with a genetic defect: ENERGY trial |
title_full_unstemmed | Extra energy for hearts with a genetic defect: ENERGY trial |
title_short | Extra energy for hearts with a genetic defect: ENERGY trial |
title_sort | extra energy for hearts with a genetic defect: energy trial |
topic | Original Article – Design Study Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439046/ https://www.ncbi.nlm.nih.gov/pubmed/30767167 http://dx.doi.org/10.1007/s12471-019-1239-0 |
work_keys_str_mv | AT vandrielbo extraenergyforheartswithageneticdefectenergytrial AT vanrossumac extraenergyforheartswithageneticdefectenergytrial AT michelsm extraenergyforheartswithageneticdefectenergytrial AT huurmanr extraenergyforheartswithageneticdefectenergytrial AT vanderveldenj extraenergyforheartswithageneticdefectenergytrial |